Adenosine A2A receptor antagonism reverses inflammation-induced impairment of microglial process extension in a model of Parkinson’s disease
Explore this paper's citation graph
Summary
The hypothesis that chronic inflammation impedes microglial motility in response to further injury, such as cell death, is supported and some aspects of the neuroprotection observed with adenosine A2A receptor antagonists may involve direct or indirect actions at microglia.
- Type
- article
- Published
- 2014-03-13
- Cited by
- 86
- References
- 58
- Access
- Open access
- OpenAlex
- https://openalex.org/W2073992121
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:29776071
Keywords
Microglia, Neuroinflammation, MPTP, Adenosine A2A receptor, Neuroprotection
References
- Analysis of Fractalkine Receptor CX3CR1 Function by Targeted Deletion and Green Fluorescent Protein Reporter Gene Insertion
- Age and Region-Specific Responses of Microglia, but not Astrocytes, Suggest a Role in Selective Vulnerability of Dopamine Neurons After 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine Exposure in Monkeys
- Pathophysiological roles for purines: adenosine, caffeine and urate
- The striopallidal neuron: a main locus for adenosine-dopamine interactions in the brain
- Activation of serotonin receptors promotes microglial injury-induced motility but attenuates phagocytic activity.
- Systemic infections and inflammation affect chronic neurodegeneration
- Reactive microglia are positive for HLA‐DR in the substantia nigra of Parkinson's and Alzheimer's disease brains
- Neuroinflammation in Parkinson’s disease: its role in neuronal death and implications for therapeutic intervention
- Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations.
- Dose-dependent destruction of the coeruleus-cortical and nigral-striatal projections by MPTP.
- Targeting adenosine A2A receptors in Parkinson's disease.
- Heterogeneity in the distribution and morphology of microglia in the normal adult mouse brain.
- Anti-inflammatory drugs and risk of Parkinson disease
- Presence of reactive microglia in monkey substantia nigra years after 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine administration
- Microglia-mediated neurotoxicity: uncovering the molecular mechanisms
- Preladenant in patients with Parkinson's disease and motor fluctuations: a phase 2, double-blind, randomised trial.
- Microglia processes block the spread of damage in the brain and require functional chloride channels
- Norepinephrine Modulates the Motility of Resting and Activated Microglia via Different Adrenergic Receptors*
- Adenosine A2A receptor antagonists exert motor and neuroprotective effects by distinct cellular mechanisms
- Protocol for the MPTP mouse model of Parkinson's disease
Cited by
- An introduction to the roles of purinergic signalling in neurodegeneration, neuroprotection and neuroregeneration.
- Purinergic signaling in Parkinson's disease. Relevance for treatment.
- Anti-inflammatory effects of Thymoquinone in activated BV-2 microglia cells
- Adenosine 2A Receptor Antagonists for the Treatment of Motor Symptoms in Parkinson's Disease
- History and Perspectives of A2A Adenosine Receptor Antagonists as Potential Therapeutic Agents
- Purinergic mechanisms in neuroinflammation: An update from molecules to behavior.
- Different danger signals differently impact on microglial proliferation through alterations of ATP release and extracellular metabolism
- Neuron–astrocyte interactions in neurodegenerative diseases: Role of neuroinflammation
- Anti-inflammatory, antioxidant, and antiparkinsonian effects of adenosine A2A receptor antagonists.
- Zonisamide suppresses endoplasmic reticulum stress-induced neuronal cell damage in vitro and in vivo.
- The two-hit hypothesis for neuroinflammation: role of exogenous ATP in modulating inflammation in the brain
- Increased free-water in the substantia nigra of Parkinson’s disease: a single-site and multi-site study
- Anti-inflammatory effects of BHBA in both in vivo and in vitro Parkinson’s disease models are mediated by GPR109A-dependent mechanisms
- Neuroprotective effects of piperine on the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson's disease mouse model.
- Non-traditional cytokines: How catecholamines and adipokines influence macrophages in immunity, metabolism and the central nervous system
- Role of Microglia Adenosine A2A Receptors in Retinal and Brain Neurodegenerative Diseases
- Selective A2A receptor antagonist prevents microglia-mediated neuroinflammation and protects retinal ganglion cells from high intraocular pressure-induced transient ischemic injury.
- Microglial P2Y12 Receptors Regulate Microglial Activation and Surveillance during Neuropathic Pain
- The efficacy of oral adenosine A2A antagonist istradefylline for the treatment of moderate to severe Parkinson’s disease
- Activation of microglial P2Y12 receptor is required for outward potassium currents in response to neuronal injury
Related papers
- Induction of reactive gliosis by purinoceptor activation: a critical appraisal.
- Adenosine A2a receptor induced gliosis via Akt/NF-kappaB pathway in vitro.
- Caffeine intake induces an alteration in human neutrophil A2A adenosine receptors
- Novel adenosine A(2A) receptor ligands: a synthetic, functional and computational investigation of selected literature adenosine A(2A) receptor antagonists for extending into extracellular space.
- C2-substituted quinazolinone derivatives exhibit A1 and/or A2A adenosine receptor affinities in the low micromolar range.
- Potential therapeutic relevance of adenosine A2B and A2A receptors in the central nervous system.
- Recent developments in the field of A2A and A3 adenosine receptor antagonists.
- Photoresponsive adenosine derivatives for optical control of adenosine A2A receptor in living cells
- 2-alkenyl and 2-alkyl derivatives of adenosine and adenosine-5'-N-ethyluronamide: different affinity and selectivity of E- and Z-diastereomers at A2A adenosine receptors.
- 2,8-Disubstituted adenosine derivatives as partial agonists for the adenosine A2A receptor.